The Jedd Wolchok Lab

The Jedd Wolchok Lab

The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.

Some of our ongoing projects include:

  • Investigation of the GITR pathway as it relates to regulatory and effector T cells.
  • Use of OX40 agonists alone and in combination with chemotherapy.
  • Exploration of the role of myeloid derived suppressor cells in tumor immunity.
  • Studying of the mechanisms underlying coordinated regulation of myeloid cells and IDO in the tumor environment and their therapeutic relevance.
  • Role of CD47 in T cell signaling.
  • Developing optimal cancer vaccine strategies in pre-clinical mouse models.
  • Role of exercise in immune checkpoint blockade.

We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.

Pictured: Jedd Wolchok

Jedd D. Wolchok, MD, PhD, FASCO

Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Melanoma and Immunotherapeutics Service; Director, Parker Institute for Cancer Immunotherapy at MSK

Professor

Research Focus

Physician-scientist Jedd Wolchok investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.

Education

  • Princeton University, Princeton, NJ BA
  • New York University, New York, NY MS
  • New York University, New York, NY PhD
  • New York University, New York, NY MD

Selected Achievements

  • The use of immunomodulatory antibodies, specifically antibodies which interfere with the CTLA-4 co-inhibitory pathway has been studied in over a dozen clinical trials. Dr. Wolchok led a phase III study of ipilimumab plus dacarbazine in patients with previously untreated metastatic melanoma. Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (Wolchok et al, NEJM 30;364(26):2517-26, 2011)